enVVeno Medical to Present Investigational enVVe System at The VEINS 2026
enVVeno Medical is scheduled to present its investigational enVVe System at The VEINS 2026 in Las Vegas on October 4, 2026, while preparing to begin enrollment in its TAVVE pivotal study.
enVVeno Medical Corporation is scheduled to showcase its investigational enVVe System at The VEINS 2026 in Las Vegas, Nevada, on Sunday, October 4, 2026. The presentation comes after the company received FDA Investigational Device Exemption approval earlier this year to begin its TAVVE pivotal trial.
Karen B. Garby, MD, DABVLM, RPhS, will present the device during the Blue Sky Breakfast, a session for specialists focused on developments in venous and vascular disease. A panel discussion and question-and-answer session are scheduled to follow.
Garby is Director of Venous Intervention at Comprehensive Integrated Care. The company describes her as an interventional radiologist with 20 years of experience in venous disease, including central and peripheral vein conditions.
enVVeno Medical describes the enVVe System as a non-surgical replacement venous valve designed to restore one-way blood flow in deep veins. The investigational device is being evaluated in a U.S. pivotal study for severe, deep venous insufficiency.
The company expects enrollment in the TAVVE study to begin in Q4 of 2026. That timing is a forward-looking statement from enVVeno Medical, and the company has cautioned that actual results and timing may differ significantly from those described or implied by such statements.
According to the company, approximately 3 million patients in the U.S. are affected by severe, deep venous insufficiency. When venous valves fail, patients may experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life.
The company says existing care primarily consists of lifelong compression therapy and wound care. These approaches are described as managing symptoms rather than correcting the underlying cause of the disease.
Rob Berman, enVVeno Medical’s Chief Executive Officer, said the summit would allow the company to introduce the enVVe System to venous specialists. He also said physicians have lacked the ability to replace damaged valves for decades and described damaged valves as the most frequent cause of severe deep venous insufficiency.
enVVeno Medical is based in Irvine, California, and is described as a late clinical-stage medical device company. Its stated focus is the development of bioprosthetic, or tissue-based, solutions for deep venous disease. The company trades on Nasdaq under the ticker NVNO.
enVVeno Medical announced that it will present its investigational enVVe ® System at The VEINS 2026 in Las Vegas, Nevada. The system is a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal study.
enVVeno Medical made the announcement on October 2, 2026.
The presentation is scheduled for Sunday, October 4, 2026, at the Blue Sky Breakfast in Las Vegas, Nevada. It will be followed by a panel discussion and Q&A session.
Karen B. Garby, MD, DABVLM, RPhS, will present the enVVe System. She is Director of Venous Intervention at Comprehensive Integrated Care and has 20 years of experience as an interventional radiologist specialising in venous disease.
The enVVe ® System is a non-surgical replacement venous valve designed to restore one-way blood flow in the deep veins. enVVeno Medical describes it as a first-in-class device intended to address the underlying cause of chronic deep venous insufficiency.
Earlier this year, enVVeno Medical received FDA Investigational Device Exemption approval to initiate the TAVVE pivotal trial for the enVVe System. The company expects enrolment in the study to begin in Q4 of 2026.
The enVVe System is being developed for severe, deep venous insufficiency, in which venous valves fail and patients can experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life. The source estimates that approximately 3 million patients in the U.S. are affected.
The source says current treatment options primarily rely on lifelong compression therapy and wound care. These approaches are described as managing symptoms rather than correcting the underlying cause of the disease.
Chief Executive Officer Rob Berman said physicians have lacked the ability for decades to replace damaged valves, which he described as the most frequent cause of severe deep venous insufficiency. He said The VEINS 2026 Summit provides an opportunity to introduce the enVVe System to venous specialists.
enVVeno Medical is an Irvine, California-based, late clinical-stage medical device company focused on advancing innovative bioprosthetic, or tissue-based, solutions for the treatment of deep venous disease. The company says its focus is improving the standard of care for that condition.
The source identifies enVVeno Medical Corporation as trading on Nasdaq under “Nasdaq:NVNO” and identifies the company in its background section as “NASDAQ: NVNO”.